Vicore Pharma

As previously announced, the company’s board of directors resolved on directed share issuances of in total 29,875,000 shares at a subscription price of SEK 16.75 per share on June 9, 2023. Through the share issuances, Vicore received issue proceeds of 500 MSEK before issue costs.

9,200,000 shares were issued and registered with the Swedish Companies Registration Office in June 2023 based on the issue authorization granted by the annual general meeting on 11 May 2023. The remaining 20,675,000 shares were issued and registered after approval by an extraordinary general meeting held on July 5, 2023.

As of today, the total number of registered shares and votes of Vicore amounts to 111,722,979. Furthermore, the registered share capital amounts to approximately SEK 55,861,488.96.

For further information, please contact:
Carl-Johan Dalsgaard, CEO, phone: +46 70 975 98 63, carl-johan.dalsgaard@vicorepharma.com  
Hans Jeppsson, CFO, phone: +46 70 553 14 65, hans.jeppsson@vicorepharma.com

This information is information that Vicore Pharma Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on July 31, 2023, at 09:00 CEST.

About Vicore Pharma Holding AB (publ)
Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in a phase 2a study of IPF. C21 is protected by US and European orphan drug designation. A variety of patents have been filed to provide further protection for C21, out to 2040 and onwards. Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. Using its unique expertise in the ATRAG biology Vicore is further fueling its pipeline with several new small molecule drug assets, with long patent life and for a variety of indications, some of which could be partnered while others may be taken to the market by Vicore.

The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.